Acknowledgment for APICES collaboration in PARASEC Study

We want to share the acknowledgment that APICES has received in PARASEC study, which is a prostate cancer retrospective study, published in the ASCO GU 2025 congress, in which APICES has collaborated in start-up, project management, monitoring, biostatistics, and medical writing activities.

This means a great motivation to all the APICES team to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank BAYER, and Dr. Javier Puente for giving us the opportunity to appear in the acknowledgments of the publication and congratulate them and all the investigators for their project success.

This retrospective study aims to descrive subsequent treatment patterns in Spanish prostate cancer patients who received darolutamide in ARAMIS trial and potentially ROS study according to standard clinical practice in Spain.

You can find further information in the following link: Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study. | Journal of Clinical Oncology